MyStart Health

About MyStart Health

MyStart Health is a 2023-founded telehealth provider offering compounded semaglutide and tirzepatide at price points between $199 and $349 per month. The company positions itself as a no-frills, affordable entry point into GLP-1 therapy, and its pricing largely delivers on that promise. At the 9 tier, MyStart Health is among the least expensive compounded semaglutide options on the market.

The platform’s approach is straightforward: complete a medical questionnaire, receive a provider review, and get medication shipped to your door. There are no elaborate wellness dashboards, coaching calls, or nutritional programs bundled into the offering. For patients who view those extras as unnecessary overhead that inflates pricing, MyStart Health’s lean model is appealing. For those who need structured support, it may feel bare-bones.

On Trustpilot, MyStart Health carries a 4.2-star rating from 300+ reviews. This is a solid score, though the review volume is modest compared to market leaders. Patients generally report satisfaction with medication quality and delivery timelines. The most common complaints relate to customer service response times and limited communication during the prescription process. The company’s C+ BBB rating sits in the middle of the pack, neither alarming nor reassuring.

Clinical oversight at MyStart Health is minimal. The platform does not include lab work, does not offer dietitian consultations, and provides limited follow-up beyond prescription renewals. This is consistent with its budget positioning but means patients must be proactive about their own health monitoring. Given that GLP-1 medications can affect kidney function, blood sugar regulation, and gastrointestinal health, independent lab work is strongly advisable for anyone using this service long-term.

MyStart Health fills a specific niche in the GLP-1 telehealth market: affordable access without extras. It is not trying to be a comprehensive weight-management program, and evaluating it as one would be unfair. Within its lane, it performs adequately, delivering compounded medications at competitive prices with acceptable patient satisfaction. The question for each patient is whether that lane is wide enough for their needs.

At a Glance